Lytix Biopharma’s technology will play a key role in future canc
«We strongly believe that Lytix Biopharma’s technology will play a key role in future cancer treatment. Therefore, we are very pleased that we have received significant interest from new investors, backing the strong commitment from our existing owners. We are now ready for the next step, initiating clinical studies in the U.S with our leading cancer treatment candidate LTX-315,” says Dr. Øystein Rekdal, CEO of Lytix Biopharma.
StockWizard
03.11.2023 kl 14:35
3580
Klart!
De har en produkt som virker og allerede en kommersiell avtale!
Når usikkerheten om emisjon blir løst, tar aksjen fart nordover.
Personlig tror jeg ikke på en katastrofeemi. siden de har en amerikansk investmentpartner med representant i styret. Derfor tror jeg at det sannsynlig blir det en gunstig avtale rettet mot proffe institusjoner i USA!
Men tiden viser snart … 🤞
Må tilføye og at Verrica terapeutics har økt nesten 20 % denne uken!
Noe er i gang …
De har en produkt som virker og allerede en kommersiell avtale!
Når usikkerheten om emisjon blir løst, tar aksjen fart nordover.
Personlig tror jeg ikke på en katastrofeemi. siden de har en amerikansk investmentpartner med representant i styret. Derfor tror jeg at det sannsynlig blir det en gunstig avtale rettet mot proffe institusjoner i USA!
Men tiden viser snart … 🤞
Må tilføye og at Verrica terapeutics har økt nesten 20 % denne uken!
Noe er i gang …
Redigert 03.11.2023 kl 14:55
Du må logge inn for å svare
StockWizard
08.11.2023 kl 12:34
3438
Spennende November med 3 internasjonale investor seminarer:
Dr Øystein Rekdal, CEO, will deliver oral presentations to institutional investors in London at the LSX Inv€$tival Showcase on the 13th of November, and attend the Jefferies Healthcare Conference on the 14th -16th November.
Later in the month, on the 23rd of November, Dr Rekdal will give a presentation at the Redeye Life Science Day 2023 in Stockholm.
Stille før stormen! Man må bare posisjonere seg! #160000++ 🤩
Dr Øystein Rekdal, CEO, will deliver oral presentations to institutional investors in London at the LSX Inv€$tival Showcase on the 13th of November, and attend the Jefferies Healthcare Conference on the 14th -16th November.
Later in the month, on the 23rd of November, Dr Rekdal will give a presentation at the Redeye Life Science Day 2023 in Stockholm.
Stille før stormen! Man må bare posisjonere seg! #160000++ 🤩
Redigert 08.11.2023 kl 12:36
Du må logge inn for å svare
Her går det fort 50% + neste dagene.
10000 aksjer på plass 6,6kr! Kjøyr!🚀
Fulgt litt med her siste dagene. Det skjer ting på kjøpersiden sagte men sikkert
StockWizard
09.11.2023 kl 10:26
3373
Oppfordrer alle å sende spørsmål til dagens presentasjon angående plan for videre finansiering og evt. emisjon!
Personlig tror jeg at dette er hoved årsak / usikkerhet som bremser kursutviklingen!
Personlig tror jeg at dette er hoved årsak / usikkerhet som bremser kursutviklingen!
Redigert 09.11.2023 kl 10:27
Du må logge inn for å svare
StockWizard
09.11.2023 kl 15:13
3378
Vi kommer til å høre mye Ila kommer 6 mnd. ! Det skjer MYE på Lytix!
De er i dialog med potensielle partnerere for videre finansiering, viser til Q&A minutt 36:15 (other plan for financing) 🤩 Det er ikke usannsynlig at de får en større investor fra USA 🤞
Jeg tør å si at dette er mest lovende biotek på OB som har gått under radaren 🤞
De er i dialog med potensielle partnerere for videre finansiering, viser til Q&A minutt 36:15 (other plan for financing) 🤩 Det er ikke usannsynlig at de får en større investor fra USA 🤞
Jeg tør å si at dette er mest lovende biotek på OB som har gått under radaren 🤞
Redigert 09.11.2023 kl 16:31
Du må logge inn for å svare
StockWizard
10.11.2023 kl 13:25
3332
Stille før stormen!
Tre internasjonale investorrettet conferanser neste uke!
På Q&A bekreftet Rekdal pågående dialog med store investorer om ‘andre planer enn emisjon’ ; se siste 5 min.
Tre internasjonale investorrettet conferanser neste uke!
På Q&A bekreftet Rekdal pågående dialog med store investorer om ‘andre planer enn emisjon’ ; se siste 5 min.
Redigert 10.11.2023 kl 14:01
Du må logge inn for å svare
StockWizard
13.11.2023 kl 09:01
3204
CEO Rekdal i London hele denne uken og presenterer for investorer i to seminarer! Ta plass 😎
Klart at de snart skal hente penger, men med deres tette bånd med USA med allerede en comnertielle avtale og PBM capital (Jaysom Rieger som styremedlem) er det lite som tyder på en krise/skandaleemisjon som andre biotek i OB!
Klart at de snart skal hente penger, men med deres tette bånd med USA med allerede en comnertielle avtale og PBM capital (Jaysom Rieger som styremedlem) er det lite som tyder på en krise/skandaleemisjon som andre biotek i OB!
Redigert 13.11.2023 kl 09:40
Du må logge inn for å svare
tirawen
14.11.2023 kl 12:36
3045
fikk kjøpt tidlig i dag, og allerede en bevegelse opp - 7,83 % ,;) men lite omsetning for øyeblikket. bunnen nådd på 5,70?
Redigert 14.11.2023 kl 12:37
Du må logge inn for å svare
tirawen
16.11.2023 kl 07:34
2878
I dag er det vel den siste dagen Lytix deltar i en helsekonferanse i London. Blir spennende å se om det kommer noe kursdrivende fra den. Den neste blir i Stockholm den 23
StockWizard
16.11.2023 kl 07:37
3087
Må minne om også presentasjon neste uke hos Redeye!
Etter siste utviklinger i selskapet kan en forvente ny analyse, derisking og kursheving fra Redeye som er deres offisiell samarbeidspartner :)
Etter siste utviklinger i selskapet kan en forvente ny analyse, derisking og kursheving fra Redeye som er deres offisiell samarbeidspartner :)
Redigert 16.11.2023 kl 09:02
Du må logge inn for å svare
Greven05
11.12.2023 kl 13:47
2143
Pga. Underliggende børsmelding.
Oslo, 11 December 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today announces that data from the ATLAS-IT-04 study has been published a paper entitled “LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma”. The paper is published in OncoImmunology, a high-profile, open access journal covering tumor immunology and immunotherapy.
The ATLAS-IT-04 trial was an open label, Phase II trial assessing the effect of LTX-315 when used in combination with Adoptive Cell Therapy (ACT) in patients with progressive metastatic soft tissue sarcoma that had failed standard of care of treatment.
The ATLAS-IT-04 trial included intra-tumoral injections of LTX-315 ahead of surgical removal of tumors, followed by in vitro expansion of T cells isolated from the resected tumor. In a second step, the expanded T cells were infused back to the patients. Six heavily pretreated patients were included in the trial and treated with LTX-315, of which four patients proceeded to adoptive T-cell therapy. The treatment was safe, and the best overall clinical response was stabilization of the disease for 208 days. The immune response data from the trial demonstrated that the treatment induces tumor specific T cells in blood, providing proof of concept that LTX-315 generates an immune response that targets the tumor.
Dr. Øystein Rekdal, CEO of Lytix commented: “This Phase II study proofs that it is feasible to combine LTX-315 and adoptive T-cell therapy and confirms that LTX-315 can induce tumor specific immune responses resulting in stabilization of the disease in sarcoma patients with otherwise progressive disease. This proof-of-concept study in patients with an unmet medical need has given us valuable information for further optimization and commercialization of our technology platform.”
The article can be found here: https://www.tandfonline.com/doi/full/10.1080/2162402X.2023.2290900
For more information, please contact:
Gjest Breistein, CFO
E-Mail:gjest.breistein@lytixbiopharma.com
Optimum Strategic Communications
Nick Bastin, Jonathan Edwards
E-mail: lytix@optimumcomms.com
Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class molecule representing a new and superior therapeutic principle to kill cancer cells and boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.
For å se meldingen følg denne linken: https://newsweb.oslobors.no/message/606165
Dette er en automatisk varsel om utsendelse av melding fra Lytix Biopharma AS.
Dersom du ikke ønsker slike varsler i fremtiden kan du følge denne linken: https://newspoint.oslobors.no/unsubscribe/AAAAAGWeiiU.U3QtZ3Jld0BvbmxpbmUubm8/no
For informasjon om hvordan Oslo Børs håndterer personinformasjon: https://www.oslobors.no/Oslo-Boers/Om-Oslo-Boers/Personvernerklaering
________________________________
This message may contain confidential information and is intended for specific recipients unless explicitly noted otherwise. If you have reason to believe you are not an intended recipient of this message, please delete it and notify the sender. This message may not represent the opinion of Euronext N.V. or any of its subsidiaries or affiliates, and does not constitute a contract or guarantee. Unencrypted electronic mail is not secure and the recipient of this message is expected to provide safeguards from viruses and pursue alternate means of communication where privacy or a binding message is desired.
For more information on the processing of your Personal Data by the Euronext Group, please refer to our privacy statement available at: https://www.euronext.com/en/privacy-policy.
Oslo, 11 December 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today announces that data from the ATLAS-IT-04 study has been published a paper entitled “LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma”. The paper is published in OncoImmunology, a high-profile, open access journal covering tumor immunology and immunotherapy.
The ATLAS-IT-04 trial was an open label, Phase II trial assessing the effect of LTX-315 when used in combination with Adoptive Cell Therapy (ACT) in patients with progressive metastatic soft tissue sarcoma that had failed standard of care of treatment.
The ATLAS-IT-04 trial included intra-tumoral injections of LTX-315 ahead of surgical removal of tumors, followed by in vitro expansion of T cells isolated from the resected tumor. In a second step, the expanded T cells were infused back to the patients. Six heavily pretreated patients were included in the trial and treated with LTX-315, of which four patients proceeded to adoptive T-cell therapy. The treatment was safe, and the best overall clinical response was stabilization of the disease for 208 days. The immune response data from the trial demonstrated that the treatment induces tumor specific T cells in blood, providing proof of concept that LTX-315 generates an immune response that targets the tumor.
Dr. Øystein Rekdal, CEO of Lytix commented: “This Phase II study proofs that it is feasible to combine LTX-315 and adoptive T-cell therapy and confirms that LTX-315 can induce tumor specific immune responses resulting in stabilization of the disease in sarcoma patients with otherwise progressive disease. This proof-of-concept study in patients with an unmet medical need has given us valuable information for further optimization and commercialization of our technology platform.”
The article can be found here: https://www.tandfonline.com/doi/full/10.1080/2162402X.2023.2290900
For more information, please contact:
Gjest Breistein, CFO
E-Mail:gjest.breistein@lytixbiopharma.com
Optimum Strategic Communications
Nick Bastin, Jonathan Edwards
E-mail: lytix@optimumcomms.com
Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class molecule representing a new and superior therapeutic principle to kill cancer cells and boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.
For å se meldingen følg denne linken: https://newsweb.oslobors.no/message/606165
Dette er en automatisk varsel om utsendelse av melding fra Lytix Biopharma AS.
Dersom du ikke ønsker slike varsler i fremtiden kan du følge denne linken: https://newspoint.oslobors.no/unsubscribe/AAAAAGWeiiU.U3QtZ3Jld0BvbmxpbmUubm8/no
For informasjon om hvordan Oslo Børs håndterer personinformasjon: https://www.oslobors.no/Oslo-Boers/Om-Oslo-Boers/Personvernerklaering
________________________________
This message may contain confidential information and is intended for specific recipients unless explicitly noted otherwise. If you have reason to believe you are not an intended recipient of this message, please delete it and notify the sender. This message may not represent the opinion of Euronext N.V. or any of its subsidiaries or affiliates, and does not constitute a contract or guarantee. Unencrypted electronic mail is not secure and the recipient of this message is expected to provide safeguards from viruses and pursue alternate means of communication where privacy or a binding message is desired.
For more information on the processing of your Personal Data by the Euronext Group, please refer to our privacy statement available at: https://www.euronext.com/en/privacy-policy.
helloween
11.12.2023 kl 14:01
2119
Nok en flott melding fra Lytix, økte på denne. God RR her på veldig lav mcap
Kursen har falt fra 10+ på lav omsetning så tenker det er på tide og få den over 10 igjen 🎅
Kursen har falt fra 10+ på lav omsetning så tenker det er på tide og få den over 10 igjen 🎅
Redigert 11.12.2023 kl 14:04
Du må logge inn for å svare
StockWizard
11.12.2023 kl 15:20
3977
Når vi blir kvitt med North Murray som lemper ut aksjer (eneste selger) og videre finansieringsplan blir klarert, ser vi helt annet kursnivå!
bulleye
19.12.2023 kl 08:57
3624
North Murray AS har i løpet av 14 dager solgt seg ned fra 840.243 aksjer til 676.814, dvs. at de GM har solgt ca.164.000 aksjer.
bulleye
20.12.2023 kl 12:12
3506
Siste oppdaterte aksjeoversikt iflg. hjemmesiden til Lytix viser at NM AS nå har 516.814 aksjer (oppdaterte pr. 15/12 ser det ut som). Dvs. at NM AS solgte 160.000 aksjer av totalt omsatt 192.600 aksjer den 15/12. Det viser hvor salgspresset kommer fra. Nå vil jeg anta Gjert Munthe er under 500.000 aksjer og ute av listen over 20 største aksjonærer ved neste oppdatering.
Redigert 20.12.2023 kl 12:12
Du må logge inn for å svare
StockWizard
20.12.2023 kl 15:17
3515
Sannsynlig behov for cash eller realisering av tap!
Det er desember vettu ;)
Det er desember vettu ;)
Serboss
02.01.2024 kl 12:02
3273
Hva skjer med Lytix...
er veien lang til produktet er på markede ?
Fase II/III ??
Mulig emi ?
er veien lang til produktet er på markede ?
Fase II/III ??
Mulig emi ?
10PS
02.01.2024 kl 14:23
3191
Blir det en emi fremover så blir det isåfall en rettet emi uten muligheter for oss å være med. Den dagen det evt. blir emi vil kursen gå rett til himmels siden økomomien da er sikret for videre utvikling. Har selv sikret meg billige aksjer på dette nivået og ser frem til neste melding fra selskapet.
bulleye
05.01.2024 kl 15:38
3071
Nå bør det være klart for en solid oppgang i Lytix, legg også merke til at her fremgår også beløpet som Lytix vil motta basert på salg. Inntekt bare for LTX-315 er 5 ganger børsverdi for Lytix.
Oslo, 5 January 2024. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical-stage immuno-oncology company, today announces that its licensing partner Verrica Pharmaceuticals Inc (“Verrica”) has reported that the last patient has been dosed in Part 2 of the Company’s Phase 2 trial of LTX-315 (named VP-315 by Verrica), a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize VP-315 for dermatologic oncology indications.
Øystein Rekdal, CEO of Lytix, commented on the results: “With this final patient dosing, Verrica has successfully completed the enrollment for Part 2 of their Phase 2 clinical trial for VP-315, a groundbreaking treatment for basal cell carcinoma. This is a significant milestone in their commitment to advancing innovative solutions for patients facing this prevalent form of skin cancer in the U.S. We look forward to the publication of the comprehensive data from their Phase 2 clinical trial later this year.”
Basal cell carcinoma is a widespread skin cancer, and patients often seek alternatives to surgery due to its associated pain, infection risks, and scarring. Verrica's VP-315 program is strategically designed to offer a targeted delivery system for the oncolytic peptide VP-315, which is specially engineered to stimulate the patient's immune system and effectively eliminate cancer cells.
About the Phase 2 Trial of VP-315
The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma. The study has enrolled 80 adult subjects with a histological diagnosis of basal cell carcinoma in at least one eligible target lesion. For additional information about this clinical trial, please visit clinicaltrials.gov, identifier NCT05188729.
Under the terms of the license agreement, Lytix was entitled to receive an upfront payment, contingent regulatory milestones based on achievement of specified development goals, and sales milestones, with aggregate payments of up to USD 111 million in total. In addition, Lytix is entitled to receive tiered royalties based on worldwide annual sales.
For more information, please contact:
Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com
Optimum Strategic Communications
Nick Bastin, Jonathan Edwards
E-mail: lytix@optimumcomms.com
Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class molecule representing a new and superior therapeutic principle to kill cancer cells and boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.
Oslo, 5 January 2024. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical-stage immuno-oncology company, today announces that its licensing partner Verrica Pharmaceuticals Inc (“Verrica”) has reported that the last patient has been dosed in Part 2 of the Company’s Phase 2 trial of LTX-315 (named VP-315 by Verrica), a potential first-in-class oncolytic peptide, for the treatment of basal cell carcinoma. Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize VP-315 for dermatologic oncology indications.
Øystein Rekdal, CEO of Lytix, commented on the results: “With this final patient dosing, Verrica has successfully completed the enrollment for Part 2 of their Phase 2 clinical trial for VP-315, a groundbreaking treatment for basal cell carcinoma. This is a significant milestone in their commitment to advancing innovative solutions for patients facing this prevalent form of skin cancer in the U.S. We look forward to the publication of the comprehensive data from their Phase 2 clinical trial later this year.”
Basal cell carcinoma is a widespread skin cancer, and patients often seek alternatives to surgery due to its associated pain, infection risks, and scarring. Verrica's VP-315 program is strategically designed to offer a targeted delivery system for the oncolytic peptide VP-315, which is specially engineered to stimulate the patient's immune system and effectively eliminate cancer cells.
About the Phase 2 Trial of VP-315
The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma. The study has enrolled 80 adult subjects with a histological diagnosis of basal cell carcinoma in at least one eligible target lesion. For additional information about this clinical trial, please visit clinicaltrials.gov, identifier NCT05188729.
Under the terms of the license agreement, Lytix was entitled to receive an upfront payment, contingent regulatory milestones based on achievement of specified development goals, and sales milestones, with aggregate payments of up to USD 111 million in total. In addition, Lytix is entitled to receive tiered royalties based on worldwide annual sales.
For more information, please contact:
Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com
Optimum Strategic Communications
Nick Bastin, Jonathan Edwards
E-mail: lytix@optimumcomms.com
Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The Company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class molecule representing a new and superior therapeutic principle to kill cancer cells and boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The Company was listed on Euronext Growth in Oslo in June 2021, following a private placement covered by investors such as PBM Capital, a US based, healthcare-focused investment firm.
Star
05.01.2024 kl 16:03
2993
ser 10 i dag? snart tomt for aksjer..
Redigert 05.01.2024 kl 16:04
Du må logge inn for å svare
X-43 scramjet
05.01.2024 kl 16:46
2897
Lytix deltar i Redeye Theme: Fight Cancer
24. januar 2024.
Kampen mot kreft er et av hovedfokusområdene i den globale bioteknologiindustrien.
Vi har invitert noen av de ledende nordiske selskapene på dette feltet til å gi oppdateringer om deres prioriteringer, utfordringer og forventet fremgang i løpet av 2024.
Arrangementet vil inkludere en introduksjon til temaet av Redeye-analytikerne Richard Ramanius og Christian Binder, som gir en oversikt over det onkologiske landskapet, sentrale trender samt kommersiell og regulatorisk aktivitet.
Bortsett fra individuelle bedriftspresentasjoner inkluderer arrangementet Q&A-sesjoner med hvert selskap samt paneldiskusjoner.
Dette kan og gi et løft i kursen. Lykke til
24. januar 2024.
Kampen mot kreft er et av hovedfokusområdene i den globale bioteknologiindustrien.
Vi har invitert noen av de ledende nordiske selskapene på dette feltet til å gi oppdateringer om deres prioriteringer, utfordringer og forventet fremgang i løpet av 2024.
Arrangementet vil inkludere en introduksjon til temaet av Redeye-analytikerne Richard Ramanius og Christian Binder, som gir en oversikt over det onkologiske landskapet, sentrale trender samt kommersiell og regulatorisk aktivitet.
Bortsett fra individuelle bedriftspresentasjoner inkluderer arrangementet Q&A-sesjoner med hvert selskap samt paneldiskusjoner.
Dette kan og gi et løft i kursen. Lykke til
helloween
05.01.2024 kl 17:02
2897
Leste melding en gang til, angrer på at eg ikke kjøpte mer i dag ass. Er jo mega bull. Tror kursen kan gå kjapt over 20 kroner
Se der ja. Handlet 10.000 aksjer i november til 6,6 og endelig smalt det her🤩🚀 så ikke nyheten før nå. Litt leit her skulle jeg hatt mer før mandags morgen
Hva sa somsa igjen? 🤪
Hva sa somsa igjen? 🤪
Redigert 05.01.2024 kl 17:50
Du må logge inn for å svare
10PS
05.01.2024 kl 21:33
2800
Lytix Biopharma får godkjent søknad om millionstøtte
Lytix Biopharma opplyser at Forskningsrådet har godkjent selskapets søknad om inntil 14,3 millioner kroner i støtte fra SkatteFUNN-ordningen.
🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀
Lytix Biopharma opplyser at Forskningsrådet har godkjent selskapets søknad om inntil 14,3 millioner kroner i støtte fra SkatteFUNN-ordningen.
🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀
X-43 scramjet
05.01.2024 kl 22:26
2761
Bare å være inne nå før mandagen er en glede. Må ha litt takknemlighet at vi er inne nå